Potassium-aggravated myotonia

Potassium-aggravated myotonia (PAM) is a group of rare inherited skeletal muscle disorders characterized by muscle stiffness (myotonia) that is worsened by the ingestion of potassium-rich foods or potassium supplementation. PAM is caused by mutations in the SCN4A gene, which encodes the voltage-gated sodium channel Nav1.4 in skeletal muscle. These gain-of-function mutations lead to abnormal sodium channel behavior, resulting in sustained muscle membrane excitability and prolonged muscle contraction (myotonia). The condition primarily affects the skeletal muscular system, and unlike hyperkalemic periodic paralysis (which also involves SCN4A mutations), PAM is not typically associated with episodes of muscle weakness or paralysis. Potassium-aggravated myotonia encompasses several clinical subtypes, including myotonia fluctuans, myotonia permanens, and acetazolamide-responsive myotonia. Myotonia fluctuans is characterized by variable day-to-day muscle stiffness that may worsen with exercise. Myotonia permanens is the most severe form, featuring continuous and generalized myotonia that can affect respiratory muscles and cause muscle hypertrophy. Acetazolamide-responsive myotonia presents with painful myotonia that responds to treatment with the carbonic anhydrase inhibitor acetazolamide. Key symptoms across all subtypes include muscle stiffness, difficulty relaxing muscles after voluntary contraction, and potential muscle pain. Symptoms are characteristically aggravated by potassium intake and are not worsened by cold exposure, which helps distinguish PAM from paramyotonia congenita. Treatment of potassium-aggravated myotonia focuses on symptom management. Sodium channel blockers such as mexiletine are considered first-line pharmacological therapy and can significantly reduce myotonia. Acetazolamide may be effective in certain subtypes. Dietary modification to avoid excessive potassium intake is also recommended. Genetic counseling is important for affected families given the autosomal dominant inheritance pattern. Prognosis is generally favorable, as the condition does not typically lead to progressive muscle degeneration, though myotonia permanens can be significantly disabling.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Potassium-aggravated myotonia